Literature DB >> 8714183

[Description of 31 pediatric cases of infection caused by human Parvovirus B 19].

B Azúa1, R Rodríguez, T Calleja, I Pocheville, C Gutiérrez, J Corral.   

Abstract

FUNDAMENTALS: [corrected] Human Parvovirus B19 has been identified as the etiological agent implicated in several clinical forms of disease. The aim of this study was to define the clinical aspects observed in the children with human parvovirus infection in our hospital.
METHODS: A retrospective study was done in 31 pediatric cases observed in our hospital from January-92 to July-94; all had positive IgM against Parvovirus (determined by enzymoinmunoanalysis).
RESULTS: The most frequent signs and symptoms were fever in 66.6% of the cases and skin findings in 48%, manifested as typical infectious erythema in 26% and polimorphic nonspecific exanthema in the rest. There were variable blood manifestations, observed in 11 children (35%): Immune Thrombocytopenic purpura, Chronic anemia in immunocompromised hosts, bone marrow erithrophagocytosis and hemolytic crises in non-hemolytic anemia patients. The abnormal blood findings were mostly observed in children with compromised immunity. Articular disease was presented in four children (12%). Long lasting fever was observed in only one case.
CONCLUSIONS: In our sample the diversity of clinical forms of presentation of Parvovirus B19 infection is well documented as it is reported by several authors. Although other studies as polymerase chain reaction (PCR), nucleic acid hybridization, direct visualization of the virus or its particles, or viral antigen detection are desirable to confirm the serologic studies.

Entities:  

Mesh:

Year:  1996        PMID: 8714183

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  1 in total

1.  [Outbreak of infectious erythema at a urban health center].

Authors:  A I Revilla Grande; T Carro García; M Sánchez de Dios; M J Galán Calvo; T Nebreda Mayoral
Journal:  Aten Primaria       Date:  2000 Jul-Aug       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.